Status:
COMPLETED
Effect of COVID-19 on Platelet Aggregation
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
COVID-19
SARS-CoV-2
Eligibility:
All Genders
18+ years
Brief Summary
This is a mechanistic, observational, prospective, case and control study, to compare platelet aggregation, analyzed by Multiplate-ADP, in hospitalized patients diagnosed with COVID-19 versus healthy ...
Detailed Description
There is strong evidence that SARS-CoV-2 infection is associated with atherothrombotic phenomena. However, platelet activity in COVID-19 has not yet been studied. Thus, the main objective of this pro...
Eligibility Criteria
Inclusion
- Agreement to sign the Free and Informed Consent Form (ICF).
- Case group: patients with up to 72 hours of hospitalization for respiratory symptoms.
- Control group: healthy volunteers, defined as having no history (confirmed or suspected) of COVID-19 or chronic diseases (except hypertension, obesity, dyslipidemia)
Exclusion
- Known platelet dysfunction or platelet count \<100,000 / µL or\> 450,000 / µL;
- Terminal illness;
- Known liver disease or clotting disorder;
- Hematocrit less than 34% or greater than 55%;
- Previous use of antiplatelet agents and / or anticoagulants (except acetylsalicylic acid and prophylactic heparin);
- Patients on invasive mechanical ventilation or receiving high oxygen flow.
Key Trial Info
Start Date :
April 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 27 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04447131
Start Date
April 29 2020
End Date
November 27 2023
Last Update
April 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
São Paulo, Brazil, 05403-900
2
Instituto de infectologia Emílio Ribas
São Paulo, Brazil